Immunoglobulin replacement products in current clinical use in the United States have poor neutralizing activity against SARS-CoV-2 Omicron strains

BACKGROUND: Intravenous (IV) and subcutaneous (SC) Immunoglobulin G (IG) replacement products are in wide use in patients with primary antibody deficiency syndrome (PAD). There is limited data on the levels of anti-SARS-CoV-2 spike antibodies in IG products or their ability to neutralize emerging SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Doss, Alexa, Liang, Chieh-Yu, Monroy, Jennifer, Wedner, James, Rigell, Christopher, Davis-Adams, Hannah, Adams, Lucas, Kendall, Peggy, Diamond, Michael, Zimmerman, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Poster Presentation Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203936/
http://dx.doi.org/10.1016/j.clim.2023.109463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203936/
http://dx.doi.org/10.1016/j.clim.2023.109463

Ejemplares similares